ArticleJournal of cellular and molecular medicine2020
Novel gene signatures for prognosis prediction in ovarian cancer.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Identification ofTranslational cancer research · 2026Article
- Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort.Communications medicine · 2025Article
- Identification of a Novel Pyroptosis-Related lncRNAs Prognosis Model and Subtypes in Ovarian Cancer.Phenomics (Cham, Switzerland) · 2025Article
- Research progress of artificial intelligence in the early screening, diagnosis, precise treatment and prognosis prediction of three central gynecological malignancies.Frontiers in oncology · 2025Review
- Senescence-Related LncRNAs: Pioneering Indicators for Ovarian Cancer Outcomes.Phenomics (Cham, Switzerland) · 2024Review
- A lactate metabolism-related signature predicting patient prognosis and immune microenvironment in ovarian cancer.Frontiers in endocrinology · 2024Article
- A prognostic model for ovarian neoplasms established by an integrated analysis of 1580 transcriptomic profiles.Scientific reports · 2023Article
- Endoplasmic Reticulum Stress-Related Ten-Biomarker Risk Classifier for Survival Evaluation in Epithelial Ovarian Cancer andInternational journal of molecular sciences · 2023Article
- Construction and validation of a prognostic model for colon adenocarcinoma based on bile acid metabolism-related genes.Scientific reports · 2023Article
- LINC00941 Promotes Cell Malignant Behavior and Is One of Five Costimulatory Molecule-Related lncRNAs That Predict Prognosis in Renal Clear Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2023Article
- Leveraging various extracellular matrix levels to assess prognosis and sensitivity to immunotherapy in patients with ovarian cancer.Frontiers in oncology · 2023Article
- Identification and validation of a pyroptosis-related prognostic model for colorectal cancer.Functional & integrative genomics · 2022Article
- Construction and validation of a transcription factors-based prognostic signature for ovarian cancer.Journal of ovarian research · 2022Article
- Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.BMC cancer · 2022Article
- Establishment, immunological analysis, and drug prediction of a prognostic signature of ovarian cancer related to histone acetylation.Frontiers in pharmacology · 2022Article
- Establishment and Analysis of an Individualized Immune-Related Gene Signature for the Prognosis of Gastric Cancer.Frontiers in surgery · 2022Article
- SNRPD1/E/F/G Serve as Potential Prognostic Biomarkers in Lung Adenocarcinoma.Frontiers in genetics · 2022Article
- Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer.Journal of oncology · 2022Article
- Overexpressed SNRPB/D1/D3/E/F/G correlate with poor survival and immune infiltration in hepatocellular carcinoma.American journal of translational research · 2022Article
- Integrating cell cycle score for precise risk stratification in ovarian cancer.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OV) is one of the leading causes of cancer deaths in women worldwide. Late diagnosis and heterogeneous treatment result to poor survival outcomes for patients with OV. Therefore, we aimed to develop novel biomarkers for prognosis prediction from the potential molecular mechanism of tumorigenesis. Eight eligible data sets related to OV in GEO database were integrated to identify differential expression genes (DEGs) between tumour tissues and normal. Enrichment analyses discovered DEGs were most significantly enriched in G2/M checkpoint signalling pathway. Subsequently, we constructed a multi-gene signature based on the LASSO Cox regression model in the TCGA database and time-dependent ROC curves showed good predictive accuracy for 1-, 3- and 5-year overall survival. Utility in various types of OV was validated through subgroup survival analysis. Risk scores formulated by the multi-gene signature stratified patients into high-risk and low-risk, and the former inclined worse overall survival than the latter. By incorporating this signature with age and pathological tumour stage, a visual predictive nomogram was established, which was useful for clinicians to predict survival outcome of patients. Furthermore, SNRPD1 and EFNA5 were selected from the multi-gene signature as simplified prognostic indicators. Higher EFNA5 expression or lower SNRPD1 indicated poorer outcome. The correlation between signature gene expression and clinical characteristics was observed through WGCNA. Drug-gene interaction was used to identify 16 potentially targeted drugs for OV treatment. In conclusion, we established novel gene signatures as independent prognostic factors to stratify the risk of OV patients and facilitate the implementation of personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.